Trastuzumab: In HER2 and Hormone Receptor Co-Positive Metastatic Breast Cancer

Authors: Orman, Jennifer S.; Perry, Caroline M.

Source: Drugs, Volume 67, Number 18, 2007 , pp. 2781-2789(9)

Buy & download fulltext article:

Price: $68.55 plus tax (Refund Policy)

Abstract:

▴ Trastuzumab is a humanised IgG₁ monoclonal antibody, which selectively binds to the human epidermal growth factor receptor 2 (HER2), inhibiting cell proliferation and survival in HER2-dependent tumours.

▴ In a randomised phase III trial in postmenopausal women with HER2 and hormone receptor (HR) co-positive metastatic breast cancer, median progression-free survival (primary endpoint) was significantly longer in patients receiving intravenous trastuzumab plus oral anastrozole than in those receiving anastrozole alone.

▴ Overall response rate and clinical benefit rate were also significantly higher, and median time to disease progression was significantly longer with trastuzumab plus anastrozole versus anastrozole alone.

▴ There were no reports of new or unexpected adverse events with trastuzumab plus anastrozole combination therapy in the randomised phase III trial.

▴ In a noncomparative phase II study of trastuzumab plus letrozole in postmenopausal women with HER2 and HR co-positive metastatic breast cancer, the majority of adverse events were mild or moderate in severity.

Keywords: Adis Drug Profiles; Breast cancer; Trastuzumab

Document Type: Research article

Affiliations: 1: Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

Publication date: 2007-01-01